YC
RCKT icon

Yarbrough Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Yarbrough Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,531
Closed -$130K – 192
2025
Q1 		$130K Hold
19,531
– – 0.01% 195
2024
Q4 		$246K Hold
19,531
– – 0.01% 177
2024
Q3 		$361K Hold
19,531
– – 0.01% 166
2024
Q2 		$421K Hold
19,531
– – 0.02% 140
2024
Q1 		$526K Hold
19,531
– – 0.02% 127
2023
Q4 		$585K Hold
19,531
– – 0.03% 119
2023
Q3 		$400K Buy
+19,531
New +$355K 0.02% 143

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Yarbrough Capital's RCKT Position: Q2 2025 in Review

Yarbrough Capital sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 19,531 shares — an estimated $130K sold.

Yarbrough Capital first reported a position in RCKT in Q3 2023 and held it in 7 quarters. The position peaked at $585K in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Yarbrough Capital reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Yarbrough Capital sold 19,531 Rocket Pharmaceuticals shares in Q2 2025, an estimated $130K.
  • Yarbrough Capital first reported a position in Rocket Pharmaceuticals in Q3 2023 and held it in 7 quarters.
  • Yarbrough Capital's Rocket Pharmaceuticals position peaked at $585K in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Yarbrough Capital's 13F filing for Q2 2025, filed 15 Jul 2025.